Skip to main navigation
Skip to Content
logo
logo
  • Overview
  • Stock
    • Stock Quote & Chart
  • News & Events
    • News Releases
    • Investor Calendar
    • Presentations
  • Financials
    • SEC Filings
    • Quarterly Results
  • Governance
    • Governance Highlights
    • Leadership
    • Board of Directors
    • Committee Composition
  • Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR

News Releases

May 12, 2023
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
Trudhesa ® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc.
Read More
May 10, 2023
Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer
SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W.
Read More
May 05, 2023
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023,
Read More
Apr 26, 2023
Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine Medications
New Analysis Indicates No Drug-Drug Interactions (DDIs) of Clinical Concern are Predicted When Recommended Doses of Trudhesa and Gepants are Co-Administered Additional Analyses from the STOP 301 Trial Show Concomitant Use of Trudhesa with Triptans and Preventative CGRP, Erenumab, Were
Read More
Apr 12, 2023
Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors
H. Stewart Parker Departing from Board SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of
Read More
Apr 11, 2023
Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual Meeting
Highlights Include Multiple Presentations Addressing Safety and Efficacy of Trudhesa SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet
Read More
Mar 24, 2023
Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Trudhesa ® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel
Read More
Mar 17, 2023
Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, March 24,
Read More
Mar 03, 2023
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Company will participate in two upcoming
Read More
Feb 22, 2023
Impel Pharmaceuticals Announces Strategic Reprioritization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity
Cost-Saving Measures Eliminate Pipeline Programs and Reduce Headcount by 16 Percent Company will Continue to Drive Trudhesa Growth Via 90 Field-Based Sales Representatives and Other Commercial Efforts Trudhesa Growth Momentum Continues, with 58 Percent Increase in New Prescriptions from  Q2 2022 to
Read More

Site - Investor Tools

Print Page
Email Alerts
RSS Feeds
Contact IR
Search
  • © 2023 Impel Pharmaceuticals Inc. All rights reserved.
  • Privacy Policy
  • Terms of Service
  • Social Media Policy
  • CA Disclosure
  • Facebook
  • Twitter
  • LinkedIn
  • Google+